Article Dans Une Revue La Presse Médicale Année : 2021

Metreleptin treatment of non-HIV lipodystrophy syndromes.

Résumé

Lipodystrophy syndromes (LS) constitute a group of rare diseases of the adipose tissue, characterized by a complete or selective deficiency of the fat mass. These disorders are associated with important insulin resistance, cardiovascular and metabolic comorbidities that impact patient's survival and quality of life. Management is challenging and includes diet, physical activity, and specific pharmacological treatment of LS-associated comorbidities. Because of a common pathophysiology involving decreased concentration of the adipokine leptin, efforts have been made to develop therapeutic strategies with leptin replacement therapy. Metreleptin, a recombinant human leptin analogue, has been proposed in hypoleptinemic patients since the beginning of 2000’s. The treatment leads to an improvement in metabolic parameters, more important in generalized than in partial LS forms. In this review, the current knowledge about the development of the drug, its outcomes in the treatment of lipodystrophic patients as well as the peculiarities of its use will be presented.
Fichier principal
Vignette du fichier
S0755498221000099.pdf (361) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04737796 , version 1 (13-11-2024)

Licence

Identifiants

Citer

Benjamin Chevalier, Madleen Lemaitre, Lysiane Leguier, Kristell Le Mapihan, Arnaud Jannin, et al.. Metreleptin treatment of non-HIV lipodystrophy syndromes.. La Presse Médicale, 2021, La Presse medicale, 50, ⟨10.1016/j.lpm.2021.104070⟩. ⟨hal-04737796⟩

Collections

RIIP UNIV-LILLE
13 Consultations
3 Téléchargements

Altmetric

Partager

More